Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06337578
Other study ID # 23C308
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 25, 2023
Est. completion date October 25, 2026

Study information

Verified date March 2024
Source Istituto Auxologico Italiano
Contact Barbara Poletti, Ph.D.
Phone +390261911
Email b.poletti@auxologico.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. Background Cognitive screening procedures via performance-based tests represent an essential, albeit preliminary, element within the diagnostic and interventional process as addressed to patients with chronic neurological disorders. Furthermore, in these populations, cognitive screening measures are often employed as outcomes in epidemiological settings, as well as endpoints in clinical trials. Therefore, cognitive screeners need to possess robust clinimetric and clinical usability properties - the investigation of which must be country-specific (i.e., specific to each language and culture). The need for such clinimetric and feasibility studies is even more true if referred to telephone-based cognitive screening (TBCS) procedures - which, until recently, have been mostly neglected in Italy, despite having the potential to bring clear benefits to clinical practice and research. In fact, TBCS techniques allow, through the use of a very widespread, accessible and easy-to-use telecommunication medium, to break down the geographical, logistical, socio-demographic and organizational barriers that make it difficult and/or prevent 1) access to these clinical services and 2) the continuity of their provision, as well as the creation and completion of 3) large-scale epidemiological studies and 4) decentralized clinical trials. However, although some TBCS tests have recently been developed and standardized in Italy, their clinimetric properties and clinical usability in populations with chronic neurological disorders have not yet been investigated. Furthermore, currently, the "paper-and-pencil" version of the international gold-standard for TBCS procedures . i.e. the Telephone Interview For Cognitive Status (TICS), which has been recently standardized in this country - is not available within the Italian scenario. In fact, although the feasibility of a de visu version of the TICS (i.e., In-Person TICS; IP-TICS) has been demonstrated in this country, an actual standardization of this test has not yet been implemented to date. Such a tool would, however, allow flexible use of screening assessments, regardless of the delivery method, both in clinical and experimental contexts. 2. Aims The present study primarily aims to provide exhaustive evidence regarding the psychometric, diagnostic and both cross-sectional and longitudinal clinical usability of TBCS that are currently available within the Italian scenario in populations with chronic neurological disorders. Secondly, this study aims to derive, in normotypical Italian subjects, 1) normative data for the IP-TICS and 2) the conversion algorithms between the latter (and other widely used "paper-and-pencil" screeners ) and the TICS. 3. Methods The study is monocentric, observational, prospective. Over a period of 3 years, patients who have already undergone an in-person cognitive screening session within 6 months prior to recruitment and falling under the following diagnostic categories will be recruited: 1) amyotrophic lateral sclerosis (N≥88); 2) Alzheimer's disease (N≥66); 3) Lewy body dementia (N≥30); 4) frontotemporal dementia (N≥30); 5) chronic cerebrovascular disorders (N≥66). Furthermore, N≥287 normotypical subjects representative of the Italian population will be recruited. The following TBCS tests will be administered to patients: 1) TICS; 2) Telephone-based Frontal Assessment Battery; 3) Telephone Language Screener; 4) Telephone-based Verbal Fluency Battery; 5) ALS Cognitive Behavioral Screen-Phone Version. Additionally, patients will undergo a functional evaluation using caregiver-report questionnaires evaluating instrumental and non-instrumental skills of daily living and behavioral changes. Normal subjects will instead be administered: 1) TICS; 2) IP-TICS; 3) Mini-Mental State Examination (MMSE); 4) Montreal Cognitive Assessment (MoCA). In patients, telephone follow-ups are expected after 6, 12 and 18 months. Statistical analyses will be carried out aimed at 1) the detailed study, in patients, of the psychometrics, diagnostics and cross-sectional/longitudinal clinical usability of the aforementioned TBCS test, as well as at 2) the derivation, in normotypical subjects, of the normative data of the IP-TICS and MoCA Memory Index Score (MIS), as well as the conversion algorithms between TICS and IP-TICS/MMSE/MoCA.


Recruitment information / eligibility

Status Recruiting
Enrollment 280
Est. completion date October 25, 2026
Est. primary completion date October 25, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion criteria: Patient cohorts: diagnosis of interest. NIs: not applicable Exclusion Criteria: Patient cohorts - age <18 years; - denial of informed consent to voluntary participation and data processing; - absence of the diagnosis of interest; - absence of a de visu cognitive screening assessment carried out in the 6 months prior to recruitment; - positive history of 1) psychiatric pathologies, 2) serious and/or uncompensated general-medical conditions and 3) uncorrected visual/hearing deficits. NIs: - age <18 years; - denial of informed consent to voluntary participation and data processing; - positive history of 1) brain disorders, 2) serious and/or uncompensated general-medical conditions and 3) uncorrected visual/hearing deficits.

Study Design


Intervention

Behavioral:
Telephone-based neuropsychological assessment - ALS
ALS patients will be administered the following TBCS tests: ALS Cognitive Behavioral Screen-Phone Version; Telephone-based Frontal Assessment Battery; Telephone Language Screener; Telephone-based Verbal Fluency Battery; This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales: Activities of Daily Living; Instrumental Activities of Daily Living; Amsterdam IADL Questionnaire - Short Version; Caregiver Behavioral Questionnaire; ECAS-Carer Interview.
Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD
AD, DLB, FTD and CVD patients will be administered the following TBCS tests: Telephone Interview for Cognitive Status; Telephone-based Frontal Assessment Battery; Telephone Language Screener; Telephone-based Verbal Fluency Battery; These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales: Activities of Daily Living; Instrumental Activities of Daily Living; Amsterdam IADL Questionnaire - Short Version; Neuropsychiatric Inventory; Frontal Behavioural Inventory.
Telephone-based and in-person cognitive screening - NIs
NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners: Mini-Mental State Examination Montreal Cognitive Assessment In-Person Telephone Interview for Cognitive Status in person.

Locations

Country Name City State
Italy Istituto Auxologico Italiano Milano

Sponsors (1)

Lead Sponsor Collaborator
Istituto Auxologico Italiano

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary ALS Cognitive Behavioral Screen-Phone Version in ALS patients ALS Cognitive Behavioral Screen-Phone Version At enrollment and at 6 months, 12 months and 18 months of follow-up
Primary Telephone Interview for Cognitive Status in AD, LBD, FTD and CVD patients Telephone Interview for Cognitive Status At enrollment and at 6 months, 12 months and 18 months of follow-up
Primary Telephone-based Frontal Assessment Battery in ALS, AD, LBD, FTD and CVD patients Telephone-based Frontal Assessment Battery At enrollment and at 6 months, 12 months and 18 months of follow-up
Primary Telephone Language Screener in ALS, AD, LBD, FTD and CVD patients Telephone Language Screener At enrollment and at 6 months, 12 months and 18 months of follow-up
Primary Telephone-based Verbal Fluency Battery in ALS, AD, LBD, FTD and CVD patients Telephone-based Verbal Fluency Battery At enrollment and at 6 months, 12 months and 18 months of follow-up
Primary Mini-Mental State Examination in NI Mini-Mental State Examination; test with minimum score of 0 and maximum score of 30 At enrollment and at 6 months, 12 months and 18 months of follow-up
Primary Montreal Cognitive Assessment in NI Montreal Cognitive Assessment; test with maximum score of 30: score of 26 or more is considered normal At enrollment and at 6 months, 12 months and 18 months of follow-up
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Completed NCT01826110 - PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers Phase 1